<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>6</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>06</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Relationship between Epidermal Growth Factor Receptor Gene Mutations and Clinicopathological Features in Patients with Non-Small Cell Lung Cancer in Western Turkey</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3705</FirstPage>
			<LastPage>3709</LastPage>
			<ELocationID EIdType="pii">27845</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; To investigate epidermal growth factor receptor (EGFR) gene mutations in patients with nonsmallcell lung cancer (NSCLC) and to analyze any relationship with clinicopathological features and prognosis.Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: EGFR gene exons 18-21 in 48 specimens of paraffin-embedded tumor tissue fromNSCLC patients were amplified by PCR, followed by direct sequencing and analysis of links to clinicopathologicalfeatures and prognosis. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: EGFR mutations were detected in 18 of 48 (42.6%) patients with NSCLC. Therewere 9 cases of mutations in exon 20, 7 in exon 19 and 2 in exon 21. Mutations were more frequently observedin women (5/7 pts, 71.4%) than in men (13/41 pts, 31.7%) (p=0.086) and in non-smokers (5/5 pts, 100%) thansmokers (13/43 pts, 30.2%). There was negative correlation of EGFR mutations with smoking status (p=0.005).EGFR mutations were more frequently observed with adenocarcinoma histology (13/32 pts, 40.6%) than in othertypes (5/16 pts, 31.3%) (p=0.527). The patients with EGFR mutations had better survival than those with wildtypeEGFR (p=0.08). There was no association of EGFR mutations with metastatic spread. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: EGFRmutations in NSCLC were here demonstrated more frequently in females, non-smokers and adenocarcinomahistology in the western region of Turkey. Patients with EGFR mutations have a better prognosis.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">EGFR mutations</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Non Small Cell Lung Cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">clinical features</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Western Turkey</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27845_8fb47f00e49c0cf35ee9b2516077252e.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
